AIMS Genetics, 2016, 3(4): 205-211. doi: 10.3934/genet.2016.4.205.

Case report

Export file:

Format

  • RIS(for EndNote,Reference Manager,ProCite)
  • BibTex
  • Text

Content

  • Citation Only
  • Citation and Abstract

Changes in FGFR2 amino-acid residue Asn549 lead to Crouzon and Pfeiffer syndrome with hydrocephalus

1 Department of Neurosurgery, Hôpital Necker-Enfants Malades, Paris, France–Centre de référence des dysostoses craniofaciales
2 Sorbonne Universités, Université Pierre et Marie Curie, Paris, France
3 Department of Biochemistry and Genetic Biology, Inserm 1132, Hôpital Lariboisière, Paris, France
4 Department of Pediatric Neurosurgery, Hôpital Neurologique Pierre Wertheimer, Lyon, France

Mutations in Fibroblast Growth Factor Receptor II (FGFR2) have been identified in patients with Crouzon and Pfeiffer syndrome, among which rare mutations of the intracellular tyrosine kinase domain. Correlating subtle phenotypes with each rare mutation is still in progress. In Necker-Enfants Malades Hospital, we identified three patients harboring three different pathogenic variants of the same amino acid residue Asn-549 located in this domain: in addition to a very typical crouzonoid appearance, they all developed clinically relevant hydrocephalus, which is an inconstant feature of Crouzon and Pfeiffer syndrome. Overall, FGFR2 tyrosine kinase domain mutations account for 5/67 (7.4%) cases in our hospital. We describe a novel mutation, p.Asn549Ser, and new cases of p.Asn549His and p.Asn549Thr mutations, each reported once before. Our three cases of Asn-549 mutations, alongside with rare previously reported cases, show that these patients are at higher risk of hydrocephalus. Clinical and imaging follow-up, with possible early surgery, may help prevent secondary intellectual disability.
  Figure/Table
  Supplementary
  Article Metrics

Keywords Craniosynostosis; craniostenosis; FGFR2; craniofacial syndrome; hydrocephalus; cavum septum pellucidum; intellectual disability

Citation: Caroline Apra, Corinne Collet, Eric Arnaud, Federico Di Rocco. Changes in FGFR2 amino-acid residue Asn549 lead to Crouzon and Pfeiffer syndrome with hydrocephalus. AIMS Genetics, 2016, 3(4): 205-211. doi: 10.3934/genet.2016.4.205

References

  • 1. Agochukwu NB, Solomon BD, Muenke M (2012) Impact of genetics on the diagnosis and clinical management of syndromic craniosynostoses. Childs Nerv Syst 28: 1447-1463.    
  • 2. Rocco FD, Arnaud E, Renier D (2009) Evolution in the frequency of nonsyndromic craniosynostosis. J Neurosurg Pediat 4: 21-25.    
  • 3. Crouzon O (1912) Dysostose cranio-faciale hereditaire. Bull Mem Soc Med Hop Paris 33: 545-555.
  • 4. Reardon W, Winter RM, Rutland P, et al. (1994) Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome. Nature Genetics 8: 98-103.    
  • 5. Collet C, Alessandri JL, Arnaud E, et al. (2014) Crouzon syndrome and Bent bone dysplasia associated with mutations at the same Tyr-381 residue in FGFR2 gene. Clin Genet 85: 598-599.
  • 6. Lajeunie E, Heuertz S, Ghouzzi VE, et al. (2006) Mutation screening in patients with syndromic craniosynostoses indicates that a limited number of recurrent FGFR2 mutations accounts for severe forms of Pfeiffer syndrome. Eur J Hum Genet 14: 289-298.    
  • 7. Lajeunie E, Ma HW, Bonaventure J, et al. (1995) FGFR2 mutations in Pfeiffer syndrome. Nat Genet 9: 108.
  • 8. Tartaglia M, Di Rocco C, Lajeunie E, et al. (1997) Jackson-Weiss syndrome: identification of two novel FGFR2 missense mutations shared with Crouzon and Pfeiffer craniosynostotic disorders. Hum Genet 101: 47-50.    
  • 9. Kan S, Elanko N, Johnson D, et al. (2002) Genomic screening of fibroblast growth-factor receptor 2 reveals a wide spectrum of mutations in patients with syndromic craniosynostosis. Am J Hum Genet 70: 472-486.
  • 10. Meyers GA, Day D, Goldberg R, et al. (1996) FGFR2 exon IIIa and IIIc mutations in Crouzon, Jackson-Weiss, and Pfeiffer syndromes: evidence for missense changes, insertions, and a deletion due to alternative RNA splicing. Am J Hum Genet 58: 491-498.
  • 11. Chen H, Ma J, Li W, et al. (2007) A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases. Mol Cell 27: 717-730.    
  • 12. Wilkie AOM, Bochukova EG, Hansen RMS, et al. (2007) Clinical dividends from the molecular genetic diagnosis of craniosynostosis. Am J Med Genet 143: 1941-1949.
  • 13. de Ravel TJL, Taylor IB, Van Oostveldt AJT, et al. (2005) A further mutation of the FGFR2 tyrosine kinase domain in mild Crouzon syndrome. Eur J Hum Genet 13: 503-505.    
  • 14. Zankl A, Jaeger G, Bonafé L, et al. (2004) Novel mutation in the tyrosine kinase domain of FGFR2 in a patient with Pfeiffer syndrome. Am J Med Genet A 131: 299-300.
  • 15. Roscioli T, Elakis G, Cox TC, et al. (2013) Genotype and clinical care correlations in craniosynostosis: findings from a cohort of 630 Australian and New Zealand patients. Am J Med Genet C Semin Med Genet 163C: 259-270.
  • 16. Collmann H, Sörensen N, Krauss J (2005) Hydrocephalus in craniosynostosis: a review. Childs Nerv Syst 21: 902-912.    
  • 17. Raybaud C, Di Rocco C (2007) Brain malformation in syndromic craniosynostoses, a primary disorder of white matter: a review. Childs Nerv Syst 23: 1379-1388.    
  • 18. McGillivray G, Savarirayan R, Cox T, et al. (2005) Familial scaphocephaly syndrome caused by a novel mutation in the FGFR2 tyrosine kinase domain. J Med Genet 42: 656-662.    

 

Reader Comments

your name: *   your email: *  

Copyright Info: 2016, Corinne Collet, et al., licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution Licese (http://creativecommons.org/licenses/by/4.0)

Download full text in PDF

Export Citation

Copyright © AIMS Press All Rights Reserved